<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5401-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZOLENAT 4 mg/5ml  Concentrate for Solution for Infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ZOLEDRONIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        82.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gensenta &#x130;la&#xE7; Sanayi ve Ticaret A.&#x15E;" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gensenta İlaç Sanayi ve Ticaret A.Ş
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GENSENTA İLAÇ SANAYI VE TICARET A.Ş
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BA08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ZOLENAT is supplied as a clear and colorless intravenous solution in a 5 ml vial. This concentrate is diluted before use. Each 5 ml of solution contains 4 mg of the active substance called zoledronic acid. ZOLENAT is one of the strong members of a group of substances called bisphosphonates.</p><p>&nbsp;</p><p>ZOLENAT is supplied in a colorless glass vial closed with a rubber stopper in packs of 1 vial.</p><p>&nbsp;</p><p>ZOLENAT is given into a vein via infusion.</p><p>&nbsp;</p><p>ZOLENAT is used in prevention of skeletal related events (e.g. fractures) in patients with bone metastases (spread of cancer from the primary cancer site to the bone) and for reducing calcium levels in patients with tumor-induced hypercalcemia. It is also used in the treatment of multiple myeloma which is a type of cancer develops in bone marrow and to prevent skeletal related events that occur in patients with advanced cancer of the bone.</p><p>&nbsp;</p><p>Zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change. This substance is used to reduce the amount of calcium in the blood where it is too high due to the presence of a tumor. Tumors can accelerate normal bone change in such a way that the release of calcium from bone is increased. This is called malign hypercalcemia.</p><p>&nbsp;</p><p>Consult your doctor if you have questions regarding why this medication is given to you.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all instructions given to you by your doctor. These instructions are may be different than the information given in this leaflet.</p><p>&nbsp;</p><p>Your doctor will carry out blood tests before you start treatment with ZOLENAT and will check your response to treatment at regular intervals.</p><p>&nbsp;</p><p><strong>a. Do not use ZOLENAT in below cases;</strong></p><p>If:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic (hypersensitive) to zoledronic acid, another bisphosphonate (the group of substances to which ZOLENAT belongs), or any of the other ingredients of this medicine,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You are pregnant,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You are breast-feeding.</p><p><strong>&nbsp;</strong></p><p><strong>b. Take special </strong><strong>care </strong><strong>with ZOLENAT:</strong></p><p>If:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You have a kidney problem (or have had),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You have asthma or you are hypersensitive to acetylsalicylic acid,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You have pain, swelling or numbness of the jaw or (a feeling of heaviness in the jaw) or loosening of a tooth (or have had),</p><p>&nbsp;</p><p>If you are having dental treatment or are due to undergo dental surgery, tell your dentist that you are being treated with ZOLENAT.</p><p>&nbsp;</p><p>Have a dental examination prior to treatment with ZOLENAT and while on treatment avoid invasive dental procedures. Get information regarding the importance of good dental hygiene and routine dental care.</p><p>&nbsp;</p><p>Your doctor will check your response to treatment at regular intervals. Your doctor will carry out blood tests before you start treatment with ZOLENAT.</p><p>&nbsp;</p><p>Do not forget to drink enough fluid before each infusion as directed by your doctor; this will help prevent you from dehydration.</p><p>&nbsp;</p><p>Reduced levels of calcium in the blood (hypocalcaemia), sometimes leading to muscle cramps, dry skin, burning sensation, have been reported in patients treated with ZOLENAT. Irregular heart beat (cardiac arrhythmia), seizures, spasm and twitching (tetany) have been reported as secondary to severe hypocalcaemia. In some instances the hypocalcaemia may be life-threatening.</p><p>&nbsp;</p><p>If these warnings are valid for you, even for a period of time in the past, please consult your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>c. Taking/using other medicines:</strong></p><p>If you are taking one of the medicines below, you may need to change your dosage and/or take other precautions:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; It is particularly important that your doctor knows if you are also taking aminoglycosides (a type of medicine used to treat severe infections) or loop diuretics (a type of medicine used to treat high blood pressure - hypertension &ndash; edema), since the combination of these with bisphosphonates may cause the calcium level in the blood to become too low.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you are taking any drugs are known to be harmful to your kidneys.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you are taking anti-angiogenic medicines (e.g. bevacizumab) as part of your cancer treatment because the combination of these medicines with bisphosphonates may increase the risk of bone damage in the jaw (osteonecrosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You should not use ZOLENAT at the same time if you are treated with other bisphosphonates (which are from the same group of medicines) and other medicines that contain zoledronic acid.</p><p>&nbsp;</p><p><em>Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without prescription.</em></p><p><strong>&nbsp;</strong></p><p><strong>d. Using ZOLENAT with food and drink</strong></p><p>Due to its method of administration, there is no objection regarding concurrent use with foods and drinks.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>e. Pregnancy &amp; Breastfeeding</strong></p><p><em>Consult your doctor or pharmacist before administration of this drug.</em></p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>If you are pregnant, or thinking about becoming pregnant, tell your doctor. The use of ZOLENAT should be avoided during pregnancy.</p><p><em>&nbsp;</em></p><p><em>During your treatment, if you realize that you are pregnant, consult to your doctor or pharmacist immediately.</em></p><p><em>&nbsp;</em></p><p><u>Breast-feeding </u></p><p>If you are breast-feeding your baby consult your doctor. It is not known whether the active substance of ZOLENAT passes to human breast milk.</p><p>&nbsp;</p><p>The use of ZOLENAT should be avoided during breast-feeding your baby.</p><p>&nbsp;</p><p><strong>f. Driving and using machines </strong></p><p>The effects of ZOLENAT on the ability to drive or use machines and performing other tasks that need full attention have not been investigated. It may cause dizziness and sleepiness. Therefore caution should be exercised while performing these kinds of tasks.</p><p>&nbsp;</p><p><strong>g. Important information regarding some of the ingredients in ZOLENAT</strong></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per 5 ml; i.e. no side effects are expected due to sodium.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>Always use ZOLENAT exactly as your doctor or health care provider has told you. You should check with your doctor, health care provider or pharmacist if you are not sure.</em></p><p>&nbsp;</p><p><strong>Instructions for proper use and dosage/frequency of administration: </strong></p><p>ZOLENAT must only be administered to patients by healthcare professionals experienced in the administration of intravenous (into a vein) bisphosphonates. Follow all the instructions carefully given by your doctor, nurse or pharmacist.</p><p>&nbsp;</p><p>The usual dose is 4 mg.</p><p>If you have a kidney problem, your doctor may administer a lower dose to you.</p><p>&nbsp;</p><p>If you are being treated in order to avoid skeleton related events, ZOLENAT infusion will be given to you every three to four weeks.</p><p>&nbsp;</p><p>If you are being treated in order to lower your blood calcium level, you will be given one infusion of ZOLENAT normally.</p><p>&nbsp;</p><p>Your doctor will decide the frequency of administration.</p><p><strong>&nbsp;</strong></p><p><strong>Administration route and method:</strong></p><p>ZOLENAT is usually given to you by infusion. This administration should continue for at least 15-30 minutes and should be a single administration without mixing with other medicines. It should be administered by healthcare professionals experienced in the administration of this group of medicines into a vein.</p><p>&nbsp;</p><p>In addition, if you do not have hypercalcemia (blood calcium levels above the normal) you may need to take oral calcium and vitamin D supplements.</p><p>&nbsp;</p><p>Your doctor will decide when ZOLENAT will be administered to you.</p><p>&nbsp;</p><p><strong>Different age groups:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Use in children:</strong></p><p>The use of zoledronic acid in children and patients under 18 years old has not been investigated, ZOLENAT is not recommended for the use in children and patients under 18 years old.</p><p>&nbsp;</p><p><strong>Use in elderly:</strong></p><p>ZOLENAT can be used in elderly. No evidence has been found that suggests any additional precautions to be taken.</p><p>&nbsp;</p><p><strong>Special conditions for use:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Kidney insufficiency:</strong></p><p>If you have a kidney problem, your doctor may give a lower dose according to the severity of your kidney problem.</p><p>&nbsp;</p><p><strong>Liver insufficiency:</strong></p><p>Limited clinical data are available in patients with severe hepatic insufficiency. If you have hepatic insufficiency, your doctor will determine the dose of ZOLENAT that you will use.</p><p>&nbsp;</p><p>Follow these instructions unless advised otherwise by your doctor.</p><p>&nbsp;</p><p><em>If you have an impression that ZOLENAT&rsquo;s effect is too strong or weak, talk to a doctor or pharmacist.</em></p><p>&nbsp;</p><p><strong>a. If you receive more ZOLENAT than you should</strong></p><p>If ZOLENAT has been administered to you more than you should receive, you may develop serum electrolyte abnormalities and changes in kidney function, including severe kidney impairment. If you have received doses of ZOLENAT higher than those recommended, you must be carefully monitored by your doctor. You may have to be given supplemental calcium by infusion.</p><p>&nbsp;</p><p><strong>b. If you forget to use ZOLENAT</strong></p><p><em>Do not take a double dose to make up for a forgotten dose.</em></p><p><strong>&nbsp;</strong></p><p><strong>c. Effects which may occur after discontinuation of ZOLENAT </strong></p><p>Your doctor will advise you how long your treatment with ZOLENAT will take. Do not stop your treatment without informing your doctor since stopping the ZOLENAT treatment may deteriorate your illness.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>SERIOUS SIDE EFFECTS:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor about any of the following serious side effects straight away:</strong></p><p><strong>&nbsp;</strong></p><p><u>Common (may affect up to 1 in 10 people):</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Severe kidney impairment (will normally be determined by your doctor with certain specific blood tests).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Low level of calcium in the blood.</p><p>&nbsp;</p><p><u>Uncommon (may affect up to 1 in 100 people):</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Pain in the mouth, teeth and/or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. These could be signs of bone damage in the jaw (osteonecrosis). Tell your doctor and dentist immediately if you experience such symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for postmenopausal osteoporosis. It is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received zoledronic acid.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reaction: shortness of breath, swelling mainly of the face and throat.</p><p><u>&nbsp;</u></p><p><u>Rare (may affect up to 1 in 1,000 people):</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; As a consequence of low calcium values: irregular heart beat (cardiac arrhythmia; secondary to hypocalcaemia).</p><p>&nbsp;</p><p><u>Very rare (may affect up to 1 in 10,000 people):</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; As a consequence of low calcium values: seizures, numbness and tetany (secondary to hypocalcaemia).</p><p><strong>&nbsp;possIble side effects:</strong></p><p><em>&nbsp;</em></p><p><em>Like all medicines, Zolenat can cause side effects, although not everybody gets them.</em></p><p>The most common ones are usually mild and will probably disappear after a short time.</p><p>&nbsp;</p><p>The below side effects may occur as a result of use of ZOLENAT:</p><p>&nbsp;</p><p>Side effects are listed as categorized below:</p><p>Very common&nbsp;&nbsp;&nbsp;&nbsp; : may affect at least 1 in 10 patients</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : may affect less than 1 in 10 but more than 1 in 100 patients</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : may affect less than 1 in 100 but more than 1 in 1.000 patients</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : may affect less than 1 in 1.000 but more than 1 in 10.000 patients</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : may affect less than 1 in 10.000 patients</p><p>Unknown&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : may affect very few patients that cannot be predicted from the available data</p><p>&nbsp;</p><p><strong>Very common:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Low level of phosphate in the blood</p><p><strong>&nbsp;</strong></p><p><strong>Common:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Headache and flu-like syndrome consisting of fever, fatigue, weakness, drowsiness, chills and bone, joint and muscle ache. In most cases no specific treatment is required and the symptoms disappear after a short time (couple of hours or days)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal reactions such as nausea and vomiting as well as loss of appetite.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Conjunctivitis (a typeof inflammation of the eye)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Low level of red blood cells (anemia)</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Skin reactions (reddness and swelling) at the administration site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure, shortness of breath, dizzinessi sleep disorders, tingling or numbness of the hands and feet, diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Low counts of white blood cells and blood platelets</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Low level of magnesium and potassium in the blood (Your doctor will monitor these levels and take any necessary measures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Tearing of the eye, eye sensitivity to light</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Sudden coldness with fainting, limpness or collapse</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Urticaria</p><p><strong>&nbsp;</strong></p><p><strong>Rare:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Slow heart beat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Confusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs)</p><p><strong>&nbsp;</strong></p><p><strong>Very rare:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fainting due to low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Severe bone, joint and muscle pain, occasionally incapacitating.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Painful redness and/or swelling of the eye.</p><p>&nbsp;</p><p><em>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</em></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>Keep ZOLENAT out of the reach and sight of children and store it in its package. </em></p><p><em>&nbsp;</em></p><p>Store the unopened package at room temperature below 30&deg;C.</p><p>&nbsp;</p><p>The prepared ZOLENAT solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the healthcare provider; the solution should be stored in refrigerator at 2&deg;C &ndash; 8&deg;C.</p><p>&nbsp;</p><p>The total time between dilutions, storage in refrigerator and end of in-use should not be longer than 24 hours.</p><p>&nbsp;</p><p><strong>Use in accordance with the expiry date.</strong></p><p><em>Do not use ZOLENAT after the expiry date which is stated on the pack.</em></p><p>&nbsp;</p><p>If you notice any defect in the product and/or on its packaging do not use ZOLENAT.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><em>Active Substance:</em></strong> Each 5 ml of concentrate contains 4 mg zoledronic acid (anhydrous) as 4.264 mg zoledronic acid monohydrate.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Excipient(s):</em></strong><strong> </strong>Mannitol, sodium citrate, water for injection.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ZOLENAT is a clear and colorless solution in colorless vial stoppered with closure and sealed with flip-off aluminum cap.
ZOLENAT 4 mg/5 ml Concentrate for Solution for IV Infusion is presented in pack containing one vial. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>Marketing Authorization Holder:&nbsp; </strong></p><p>MN Pharmaceuticals</p><p>İş Kuleleri, Levent Mah., Meltem Sok.</p><p>No: 10 Kule: 2 Kat: 24</p><p>4. Levent, Beşiktaş, İstanbul/TURKEY</p><p>Tel: +90.212 337 38 00</p><p>Fax: +90.212.337 38 01</p><p>e-mail: info@mn.com.tr</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer:</strong></p><p>MN Pharmaceuticals</p><p>Sanayi Cad. No: 13</p><p>Yenibosna &ndash; Bah&ccedil;elievler - Istanbul</p><p>TURKEY</p><p><em>&nbsp;</em></p><p><em>For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:</em></p><p>Kingdom of Saudi Arabia</p><p>Salehiya Trading Est.</p><p>P.O. Box: 991 Riyadh: 11421</p><p>Tel. No.: +966 11 464 6955</p><p>Fax No.: +966 11 463 4362</p><p>Website: www.salehiya.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 03/2019; version number 02
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يتوفر زولينات في صورة محلول نقى عديم اللون خاص بالحقن الوريدي في قنينة بحجم ٥ مل. يجب تخفيف هذا المحلول المركّز قبل الاستخدام. كل ٥ مل من المحلول تحتوي على ٤ مجم من المادة الفعّالة التي تُدعى حامض الزوليدرونيك. يعتبر زولينات واحدًا من العناصر القوية ضمن مجموعة مواد تُسمى &quot;البيفوسفونات &quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر زولينات في قنينة زجاجية عديمة اللون مغلقة بواسطة سدادة مطاطية في عبوات كل منها يحوى قنينة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء محلول زولينات في الوريد عن طريق التسريب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم زولينات من أجل الوقاية من الأحداث المرتبطة بالهيكل العظمي (مثل الكسور) في المرضى الذين يعانون من نَقائِل العظام (انتشار السرطان من موضع السرطان الأولي إلي العظام)، وأيضا من أجل تقليل مستويات الكالسيوم عند المرضى الذين يعانون من فرط كالسيوم الدم الناجم عن ورم. ويستخدم أيضًا في علاج المايلوما المتعددة، وهي نوع من السرطان يصيب نخاع العظام، وذلك للوقاية من الأحداث المرتبطة بالهيكل العظمى التي تحدث عند المرضى الذين يعانون من مراحل متقدمة لسرطان العظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل حامض الزوليدرونيك عن طريق تعليق نفسه بالعظام وبذلك يُبطئ من معدل تغُّير العظام. تستخدم هذه المادة لتقلل من كمية الكالسيوم الموجود في الدم عندما تكون عالية جدًا بسبب وجود ورم. يمكن للأورام أن تُسرع من عملية تغيّر العظام الطبيعية بطريقة تزيد من عملية إطلاق الكالسيوم منها. &nbsp;وهذا ما يسمى: فرط كالسيوم الدم الخبيث.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك سؤالًا حول سبب إعطاءك هذا الدواء، استشر الطبيب الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع جميع التعليمات التي يعطيها لك طبيبك. قد تكون هذه التعليمات مختلفة عن المعلومات الواردة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم طبيبك بإجراء فحوصات للدم قبل بدء العلاج بمحلول زولينات، وسوف يتفقد استجابتك للعلاج على فترات زمنية منتظمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ- لا تستخدم زولينات في الحالات التالية: </strong></p><p dir="RTL">إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعانى من حساسية (فرط الحساسية) ضد حامض الزوليدرونيك، أو ضد أي دواء آخر من مجموعة &quot;البيفوسفونات &quot; (مجموعة المواد التي ينتمي لها زولينات)، أو ضد أي مكون آخر من مكونات هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ حاملاً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ ترضعين طفلاً.</p><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>ب- يجب توخي الحذر الشديد بخصوص زولينات: </strong></p><p dir="RTL">إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني (أو سبق لك أن عانيت) من مشكلة في الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من ربو أو حساسية ضد حامض الأسيتيل ساليسيليك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني (أو قد عانيت سابقًا) من ألم أو تورم أو تنميل في الفك أو (شعور بثقل في الفك) أو ضعف في الأسنان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت خاضعًا لعلاج أسنان أو من المقرر إجراء جراحة أسنان لك، عليك إخبار طبيب الأسنان الخاص بك أنك تخضع للعلاج باستخدام زولينات.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">عليك الخضوع لفحص أسنان قبل العلاج باستخدام زولينات، وأيضًا تجنب إجراءات الأسنان الغازية أثناء فترة العلاج. احصل على معلومات فيما يتعلق بأهمية صحة الأسنان والرعاية الروتينية لها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم طبيبك بمتابعة استجابتك للعلاج على فترات زمنية منتظمة، وسيقوم بإجراء فحوصات الدم قبل بدء العلاج باستخدام زولينات. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تنس أن تشرب ما يكفي من السوائل قبل كل تسريب حسب توجيهات الطبيب، لأن هذا سيساعد على وقايتك من الجفاف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تم الإبلاغ عن انخفاض مستويات الكالسيوم في الدم (نقص الكالسيوم في الدم) عند المرضى الخاضعين للعلاج باستخدام زولينات، مما يؤدي في بعض الأحيان إلى تشنجات عضلية، وجفاف في الجلد، وإحساس حارق. وأيضًا تم الإبلاغ عن عدم انتظام ضربات القلب ونوبات وتقلص وارتعاش (تكزز) كأعراض ثانوية للنقص الحاد للكالسيوم في الدم. قد يمثل نقص الكالسيوم في الدم، في بعض الحالات، تهديدًا للحياة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت هذه التحذيرات صحيحة بالنسبة لك، ولو لفترة من الزمن في الماضي، يرجى استشارة الطبيب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ج- تعاطي/ استخدام أدوية أخرى: </strong></p><p dir="RTL">إذا كنت تتناول واحدًا من الأدوية التالية، فقد تحتاج لتغيير الجرعة و/أو لاتخاذ احتياطات أخرى:&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم جدًا أن يكون طبيبك على علم إذا كنت تتناول أمينوغليكوزيد (دواء يستخدم لعلاج العدوى الشديدة) أو مُدرات البول التي تعمل على ثنية هنل (أدوية تستخدم لعلاج ضغط الدم المرتفع - ارتفاع ضغط الدم - وزمة)، لأن تعاطي هذه الأدوية مع مجموعة &quot;البيفوسفونات&quot; قد يؤدي إلى الانخفاض الشديد لمستوى الكالسيوم في الدم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت تتناول أي أدوية معروفة بأنها ضارة بالنسبة للكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت تتناول أي أدوية أخرى مضادة لتَوَلُّد الأَوعِيَة الدموية (مثل: بيفاسيزوماب) كجزء من علاج السرطان لديك، لأن تناول هذه الأدوية مع مجموعة &quot;البيفوسفونات&quot; قد يؤدى إلى زيادة خطر حدوث تلف عظام الفك (نخر العظام).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استخدام زولينات في نفس الوقت الذي تخضع فيه للعلاج باستخدام دواء آخر من مجموعة &quot;البيفوسفونات &quot; (أي من نفس المجموعة الدوائية) أو أي أدوية تحتوي على حامض الزوليدرونيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الرجاء إخبار الطبيب أو الصيدلي الخاص بك إذا كنت تأخذ أو أخذت حديثًا أية أدوية أخرى؛ بما فيها الأدوية التي تُستخدم بدون وصفة طبية. </em></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>د- استخدام محلول زولينات مع الطعام والشراب:</strong></p><p dir="RTL">نظرًا لأن زولينات يستخدم عن طريق الوريد، فلا يوجد أي مانع لاستخدامه في نفس الوقت مع الأطعمة أو المشروبات.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>هـ- الحمل والرضاعة:</strong></p><p dir="RTL"><em>استشيري الطبيب أو الصيدلي الخاص بك قبل تعاطي هذا الدواء. </em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">اخبري طبيبك إذا كنتِ حاملاً أو كنتِ تخططين لذلك. يجب تجنب استخدام زولينات أثناء الحمل.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>إذا اكتشفتِ حدوث حمل أثناء فترة العلاج باستخدام زولينات، فيجب استشارة الطبيب أو الصيدلي على الفور.&nbsp; </em></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><u>الرضاعة</u><u> </u></p><p dir="RTL">إذا كنتِ ترضعين طفلاً، فعليك استشارة طبيبك. من غير المعرف ما إذا كانت المادة الفعّالة لدواء زولينات تمر عبر حليب الثدي في البشر أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب تجنب استخدام زولينات أثناء فترة الرضاعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و- القيادة واستخدام الآلات:</strong><strong> </strong></p><p dir="RTL">لم يتم بعد فحص تأثير زولينات على القدرة على القيادة أو استخدام الآلات والقيام بالمهمات الأخرى التي تتطلب المزيد من التركيز. قد يسبب زولينات دوخة ونعاس. &nbsp;لذلك يجب توخي الحذر عند القيام بهذا النوع من المهام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ز- معلومات هامة بشأن بعض المكونات الموجودة في زولينات:</strong></p><p dir="RTL">هذا المنتج الدوائي يحتوي على أقل من ١ ملليمول من الصوديوم (٢٣ مجم) في كل ٥ مل؛ أي أنه ليس من المتوقع حدوث آثار جانبية بسبب الصوديوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>استخدم زولينات تمامًا كما أخبرك الطبيب أو مُقدم الرعاية الصحية الخاص بك.</em><em> </em><em>عليك مراجعة الطبيب أو الصيدلي أو مُقدم الرعاية الصحية في حالة ما إذا كنت غير متأكد. </em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات من أجل الاستخدام الصحيح وجرعة/مرات التعاطي: </strong><strong>&nbsp;</strong></p><p dir="RTL">يجب إعطاء دواء زولينات للمريض بواسطة مُقدم رعاية صحية له خبرة في إعطاء مجموعة &quot;البيفوسفونات&quot; عن طريق الوريد. اتبع جميع التعليمات المقدمة لك من الطبيب أو الصيدلي أو الممرض بحرص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة هي ٤ مجم.</p><p dir="RTL">إذا كنت تعاني من مشكلة في الكلى، فقد يعطيك الطبيب جرعة أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تخضع للعلاج من أجل الوقاية من الأحداث المرتبطة بالهيكل العظمي، فسوف يتم إعطاءك زولينات من خلال التسريب الوريدي كل ثلاثة أو أربعة أسابيع. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كنت تخضع للعلاج من أجل خفض مستوى الكالسيوم في الدم، فسوف يتم إعطاءك زولينات من خلال التسريب الوريدي مرة واحدة عادةً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يقرر الطبيب عدد مرات التعاطي. &nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>طريقة ومسار التعاطي: </strong></p><p dir="RTL">يتم إعطاءك دواء زولينات عادةً بواسطة التسريب الوريدي. يجب أن يستمر التسريب لمدة لا تقل عن ١٥-٣٠ دقيقة، ويجب أن يكون تسريبًا فرديًا دون خلط أي دواء آخر. كما يجب تعاطيه بواسطة مُقدم رعاية صحية لديه خبرة في إعطاء هذه المجموعة من الأدوية عن طريق الوريد.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">بالإضافة إلى ذلك، إذا لم تكن تعاني من فرط كالسيوم الدم (مستوى الكالسيوم في الدم فوق المستوى الطبيعي)، فقد تحتاج لتناول مكملات الكالسيوم وفيتامين &quot;د&quot; عن طريق الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يحدد طبيبك الوقت المناسب لإعطائك دواء زولينات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المجموعات العمرية المختلفة:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاستخدام مع الأطفال: </strong></p><p dir="RTL">لم يتم بعد فحص استخدام حامض الزوليدرونيك مع الأطفال والمرضى الذين تقل أعمارهم عن ١٨ عامًا، لذا لا ينصح باستخدام دواء زولينات مع الأطفال والمرضى الذين تقل أعمارهم عن ١٨ عامًا.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام مع المسنين: </strong></p><p dir="RTL">يمكن استخدام زولينات مع المسنين. لم يتم إيجاد أي دليل يقترح اتخاذ أي إجراءات احترازية إضافية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حالات استخدام خاصة: </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قصور الكلى: </strong></p><p dir="RTL">إذا كنت تعاني من مشكلة في الكلى، فقد يعطيك الطبيب جرعة أقل بالتناسب مع حدة مشكلة الكلى لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قصور الكبد: </strong></p><p dir="RTL">المعلومات الطبية المتاحة، بشأن المرضى الذين يعانون من قصور كبدي حاد محدودة. إذا كنت تعاني من قصور في الكبد، فسوف يحدد طبيبك جرعة زولينات التي سوف تتناولها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتبع هذه التعليمات ما لم ينصحك طبيبك بغيرها. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>إذا كان لديك انطباعاً يفيد بأن تأثير زولينات قوي جدًا أو ضعيف جدًا، تحدث إلي الطبيب أو الصيدلي الخاص بك. </em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ- إذا تعاطيت المزيد من دواء زولينات أكثر مما يجب:</strong></p><p dir="RTL">إذا تم إعطاءك زولينات بكمية تزيد عن الكمية التي يجب إعطاءها لك، فقد تُصاب باضطرابات مستوي الكهارل في المصل وتغييرات في وظائف الكلى، بما في ذلك قصور الكلى الحاد. إذا تلقيت جرعات من زولينات أكتر من تلك الموصوفة لك، فيجب أن تتم مراقبتك بحرص بواسطة طبيبك. قد تحتاج لتعاطي الكالسيوم التكميلي عن طريق التسريب الوريدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب- إذا نسيت استخدام دواء زولينات:</strong></p><p dir="RTL"><em>لا تأخذ جرعة مضاعفة من أجل تعويض الجرعة المنسية. </em></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ج- التأثيرات التي قد تحدث بعد توقف العلاج باستخدام زولينات: </strong></p><p dir="RTL">سوف ينصحك الطبيب بشأن المدة التي سوف يستغرقها علاجك باستخدام زولينات. لا توقف العلاج دون إعلام طبيبك، لأن توقفك عن تعاطي زولينات قد يزيد حالتك سوءًا. &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أبلغ طبيبك عن أي من الآثار الجانبية الخطيرة التالية على الفور: </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>شائعة (تحدث عند ما يصل إلى شخص واحد من بين كل ١٠ أشخاص):</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; قصور الكلى الحاد (ويحدد طبيبك ذلك عادةً باستخدام اختبارات دم معينة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الكالسيوم في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>غير شائعة (تحدث عند ما يصل إلى شخص واحد من بين كل ١٠٠ شخص):</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الفم و/أو الأسنان و/أو الفك، أو تورم وتقرح داخل الفم، أو تنميل أو الشعور بثقل في الفك، أو ضعف الأسنان. &nbsp;قد تكون هذه أعراض لتلف العظام في الفك (نخر العظام). إذا عانيت من مثل هذه الأعراض، أخبر طبيبك أو طبيب الأسنان فورًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تم ملاحظة عدم انتظام ضربات القلب (الرجفان الأذيني) عند المريضات اللاتي يتلقين حمض الزوليدرونيك لعلاج هشاشة العظام بعد انقطاع الطمث، ولكن من غير الواضح حاليًا ما إذا كان حمض الزوليدرونيك يسبب عدم انتظام ضربات القلب هذا أم لا، لذا يجب عليك إبلاغ طبيبك إذا عانيت من مثل هذه الأعراض بعد أن كنت قد تعاطيت حمض الزوليدرونيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية المحتملة</strong>:</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>شأنه شأن جميع الأدوية، قد يسبب محلول زولينات آثارًا جانبية، وإن لم يعاني منها الجميع. </em></p><p dir="RTL">الأعراض الأكثر شيوعًا تكون معتدلة عادةً ومن المحتمل أن تختفي بعد وقت قصير.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">قد تحدث الآثار الجانبية التالية كنتيجة لاستخدام زولينات:</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية مدرجة ومصنفة كما يلي: &nbsp;</p><p dir="RTL">تأثيرات شائعة جدًا&nbsp;&nbsp;&nbsp;&nbsp; : تؤثر على مريض واحد على الأقل من بين كل ١٠ مرضى.</p><p dir="RTL">تأثيرات شائعة&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : تؤثر على أقل من مريض واحد من بين كل ١٠ مرضى ولكن أكثر من مريض واحد من بين كل ١٠٠ مريض.</p><p dir="RTL">تأثيرات غير شائعة&nbsp;&nbsp;&nbsp; : تؤثر على أقل من مريض واحد من بين كل ١٠٠ مريض ولكن أكثر من مريض واحد من بين كل 1000 مريض.</p><p dir="RTL">تأثيرات نادرة&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : تؤثر على أقل من مريض واحد من بين كل 1000 مريض ولكن أكثر من مريض واحد من بين كل &nbsp;&nbsp;10000 مريض.</p><p dir="RTL">تأثيرات نادرة جدًا&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : تؤثر على أقل من مريض واحد من بين كل 10000 مريض.</p><p dir="RTL">تأثيرات غير معروفة : قد تؤثر على عدد ضئيل من المرضى ولا يمكن توقعها باستخدام البيانات المتاحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات شائعة جدًا: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الفوسفات في الدم. &nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثيرات شائعة: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صداع، ومتلازمة تشبه الأنفلونزا تتكون من حمى وتعب ووهن ودوخة ورعشة وألم في العظام والمفاصل والعضلات. في معظم الحالات لا يتطلب الأمر علاجاً معيناً وتختفي الأعراض بعد وقت قصير (بضع ساعات أو أيام).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات خاصة بالجهاز الهضمي، مثل الدوخة والقيء بالإضافة إلى فقدان الشهية. &nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الملتحمة (نوع من التهاب العين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نقص مستوى خلايا الدم الحمراء (أنيميا).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثيرات غير شائعة: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات فرط الحساسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية (احمرار وتورم) في مكان التعاطي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم، وضيق في التنفس، ودوخة، واضطرابات في النوم، ووخز أو تنميل في اليدين والقدمين، وإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد خلايا الدم البيضاء وصفائح الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الماغنسيوم والبوتاسيوم في الدم (سوف يرصد طبيبك هذه المستويات ويتخذ التدابير الضرورية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نُعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إدماع العين، وحساسية العين ضد الضوء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; برودة مفاجئة مع إغماء، وإنهاك أو ارتخاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; شَرَى</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثيرات نادرة:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; بطء نبض القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; قد يحدث، نادرًا، كسر غير اعتيادي في عظم الفخذ خاصة في المرضى الخاضعين لعلاج طويل الأمد لهشاشة العظام. اتصل بطبيبك إذا عانيت من ألم أو ضعف أو عدم ارتياح في الفخذ أو الورك أو الأربية لأن هذا قد يكون مؤشرًا مبكرًا على وجود كسر ممكن من عظم الفخذ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مرض الرئة الخلالي (التهاب الأنسجة حول أكياس الهواء في الرئتين(.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثيرات نادرة جدًا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء بسبب ضغط الدم المنخفض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; آلام شديدة في العظام والمفاصل والعضلات، قد تكون مسببة للعجز في بعض الأحيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; احمرار و/أو تورم مؤلم في العين.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p dir="RTL"><em>إذا لاحظت أية أعراض أخرى لم تُذكر في هذه النشرة أو أصبحت بعض الآثار الجانبية حادة، من فضلك، أبلغ بها الطبيب أو الصيدلي الخاص بك. </em></p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية حادة: ضيق في التنفس، وتورم في الوجه والحلق بشكل أساسي.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>نادرة (تحدث عند ما يصل إلى شخص واحد من بين كل 1000 شخص):</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنتيجة لانخفاض قيم مستوى الكالسيوم: نبض القلب غير المنتظم (عدم انتظام ضربات القلب؛ عرض ثانوي لنقص مستوى الكالسيوم في الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>نادرة جدًا (تحدث عند ما يصل إلى شخص واحد من بين كل 10000 شخص):</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنتيجة لانخفاض قيم مستوى الكالسيوم:&nbsp; نوبات، وتنميل، وتَكَزُّز (أعراض ثانوية لنقص مستوى الكالسيوم في الدم).&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><em>احفظ زولينات بعيدًا عن متناول ورؤية الأطفال وخزنه في عبوته الخاصة. </em><em>&nbsp;</em></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">خزن العبوات غير المفتوحة في درجة حرارة الغرفة تحت ٣٠ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب استخدام محلول زولينات المُعد للتسريب على الفور. إذا لم يستخدم المحلول على الفور، فيجب تخزينه في الثلاجة أو في درجة حرارة تتراوح بين ٢ و٨ درجات مئوية. ظروف ووقت التخزين قبل الاستخدام هي مسؤولية مُقدم الرعاية الصحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا يتعدى الوقت الكلى، بين التخفيف والتخزين في الثلاجة ونهاية وقت الاستخدام، ٢٤ ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يستخدم وفقًا لتاريخ انتهاء الصلاحية. </strong></p><p dir="RTL"><em>لا تستخدم زولينات بعد تاريخ انتهاء الصلاحية المدون على العبوة. </em></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم زولينات إذا لاحظت أي عيب في المنتج و/أو العبوة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><em>المادة الفعّالة:</em></strong> كل ٥ مل من المحلول المركّز تحتوي على ٤ مجم من حامض الزوليدرونيك (منزوع الماء) تكافئ 4.264 مجم من مونوهيدرات حامض الزوليدرونك.</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong>السواغات</strong>: مانّيتول، وسترات الصوديوم، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><em>ب- ما هو شكل محلول زولينات وما هي محتويات العبوة:</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">زولينات هو محلول نقي عديم اللون موجود داخل قنينة عديمة اللون مغلقة بسدادة ومُحكمة باستخدام غطاء من الألومنيوم قابل للنزع.</p><p dir="RTL">يتوفر محلول زولينات ٤ مجم/ ٥ مل المركز المخصص للتسريب الوريدي، في عبوة تحتوى على قنينة واحدة. &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حامل ترخيص التسويق: </strong><strong>&nbsp;&nbsp;&nbsp; </strong></p><p>MN Pharmaceuticals</p><p>İş Kuleleri, Levent Mah., Meltem Sok.</p><p>No: 10 Kule: 2 Kat: 24</p><p>4. Levent, Beşiktaş, İstanbul/TURKEY</p><p>Tel: +90.212 337 38 00</p><p>Fax: +90.212.337 38 01</p><p>e-mail: info@mn.com.tr</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المصنعة: </strong></p><p>MN Pharmaceuticals</p><p>Sanayi Cad. No: 13</p><p>Yenibosna &ndash; Bah&ccedil;elievler - Istanbul</p><p>TURKEY</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">من أجل أي معلومات حول هذا المنتج الدوائي، من فضلك، اتصل بالممثل المحلي لحامل رخصة التسويق:</p><p dir="RTL">&nbsp;</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">مؤسسة الصالحية للتجارة</p><p dir="RTL">صندوق بريد رقم: ٩١١ &nbsp;الرياض: &nbsp;١١٤٢١</p><p dir="RTL">هاتف رقم :٠٠٩٦٦١١٤٦٤٦٩٥٥</p><p dir="RTL">فاكس رقم : &nbsp;٠٠٩٦٦١١٤٦٣٤٣٦٢</p><p dir="RTL">الموقع الإلكتروني: &nbsp;www.salehiya.com</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النشرة آخر مرة في11/2019  ؛ الإصدار رقم 02. 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZOLENAT 4 mg/5ml Concentrate for Solution for IV Infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substance:
Each 5 ml concentrated solution:
Zoledronic acid (anhydrous)	4 mg (as 4.264 mg zoledronic acid monohydrate)

Excipients:
Sodium citrate	24 mg

For a full list of other excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.
Clear, colorless solution in 5 ml vial.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zolenat is indicated for prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or hypercalcemia) in patients with multiple myeloma with shown lytic lesions by radiological techniques and in patients with advanced cancer involving bone metastases and in treatment of patients with hypercalcemia of malignancy (defined as an albumin-corrected calcium (cCa) of greater than or equal to 12 mg/dL [3.0 mmol/L]).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology/frequency and duration of administration:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Prevention of skeletal related events in patients with advanced cancer involving bone</strong></p><p><u>&nbsp;</u></p><p><u>Adults and elderly</u></p><p>The recommended dose in the prevention of skeletal related events in patients with advanced cancer involving bone is 4 mg zoledronic acid. Concentrate for solution should be diluted with 0.9% sodium chloride or 5% dextrose solution and should be given by intravenous infusion over at least 15-30 minutes once every 3 to 4 weeks.</p><p>Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily.</p><p>&nbsp;</p><p><strong>Treatment of hypercalcemia of malignancy</strong><strong> </strong></p><p><u>&nbsp;</u></p><p><u>Adults and elderly</u></p><p>The recommended dose for adults and elderly in hypercalcemia (albumin-corrected serum calcium &ge; 12.0 mg/dl or 3.0 mmol/l) is 4 mg zoledronic acid. Concentrate for solution should be diluted with 0.9% sodium chloride or 5% dextrose solution and should be given by a single intravenous infusion over at least 15-30 minutes. Patients must be maintained well hydrated prior to and following administration of ZOLENAT.</p><p><u>&nbsp;</u></p><p><strong>Method of administration:</strong></p><p>ZOLENAT must only be administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.</p><p>&nbsp;</p><p>ZOLENAT concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer&#39;s solution, and should be administered as a single intravenous solution in a separate infusion line.</p><p>&nbsp;</p><p>Patients must be maintained well hydrated prior to and following administration of ZOLENAT.</p><p><strong>&nbsp;</strong></p><p><strong>Instructions for preparing reduced doses of ZOLENAT</strong></p><p>Patients with mild to moderate renal impairment defined as CLcr 30-60 ml/min, reduced dosages of ZOLENAT are recommended except the ones hypercalcemia of malignancy.</p><p>&nbsp;</p><p>Withdraw an appropriate volume of the concentrate for solution to prepare reduced doses of ZOLENAT, as indicated below:</p><p>&nbsp;</p><p>4.4 ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for 3.5 mg dose</p><p>4.1 ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for 3.3 mg dose</p><p>3.8 ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for 3.0 mg dose</p><p>&nbsp;</p><p>The withdrawn amount of concentrate for solution should be diluted with sterile 0.9% sodium chloride or 5% Dextrose solution. Dosage should be administered as single intravenous infusion and within not less than 15-30 minutes.</p><p><strong>&nbsp;</strong></p><p><strong>Additional information regarding special populations:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Renal insufficiency:</strong></p><p>ZOLENAT treatment in patients with hypercalcemia of malignancy (HCM) who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment. In the clinical studies, patients with serum creatinine &gt; 400 &micro;mol/l or &gt; 4.5 mg/dl were excluded. No dose adjustment is necessary in patients who are treated for hypercalcemia of malignancy and with serum creatinine &lt; 400 &micro;mol/l or &lt; 4.5 mg/dl (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p>Prevention of skeletal related events in patients with advanced malignancies involving bone:</p><p>When initiating treatment with ZOLENAT in patients with multiple myeloma or metastatic bone lesions from solid tumors, serum creatinine and creatinine clearance (CLcr) should be determined. CLcr is calculated from serum creatinine levels using the Cockcroft-Gault formula. ZOLENAT is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr &lt; 30 ml/min. In clinical trials with zoledronic acid, patients with serum creatinine &gt; 265 &micro;mol/l or &gt; 3.0 mg/dl were excluded.</p><p>&nbsp;</p><p>In patients with bone metastases presenting with mild to moderate renal impairment (CLcr 30-60 ml/min) prior to initiation of therapy, the following ZOLENAT dose is recommended (see also section 4.4):</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Baseline creatinine clearance (ml/min)</p></td><td><p>Recommended ZOLENAT dosage*</p></td></tr><tr><td><p>&gt;60</p></td><td><p>4.0 mg</p></td></tr><tr><td><p>50-60</p></td><td><p>3.5 mg*</p></td></tr><tr><td><p>40-49</p></td><td><p>3.3 mg*</p></td></tr><tr><td><p>30-39</p></td><td><p>3.0 mg*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*Doses have been calculated assuming target AUC (Area under the curve) of 0.66 (mg&bull;hr/1) (CLcr = 75 ml/min). The reduced doses for patients with renal impairment are expected to achieve the same AUC as that seen in patients with creatinine clearance of 75 ml/min.</p></td></tr></tbody></table><p>&nbsp;</p><p>Following initiation of therapy, serum creatinine should be measured prior to each dose of ZOLENAT and treatment should be withheld if renal function has deteriorated. In the clinical trials, renal deterioration was defined as follows:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients with normal baseline serum creatinine (&lt;1.4 mg/dl) an increase of &ge;0.5 mg/dl</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients with abnormal baseline creatinine (&gt; 1.4 mg/dl), an increase of &ge;1.0 mg/dl</p><p>&nbsp;</p><p>In the clinical studies, zoledronic acid treatment was resumed only when the creatinine level returned to within 10% of the baseline value (see section 4.4 Special warnings and precautions for use). ZOLENAT treatment should be resumed at the same dose as that given prior to treatment interruption.</p><p>&nbsp;</p><p><strong>Hepatic insufficiency:</strong> As only limited clinical data are available in patients with severe hepatic insufficiency, no specific recommendations can be given for this patient population.</p><p>&nbsp;</p><p><strong>Pediatric population: </strong>The safety and efficacy of zoledronic acid in pediatric patients have not been established.</p><p>&nbsp;</p><p><strong>Geriatric population:</strong> No special dose adjustment is necessary for elderly.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	ZOLENAT is contraindicated in patients with clinically significant hypersensitivity to zoledronic acid or to other bisphosphonates or one of the excipients.
•	It is contraindicated in pregnancy and breast-feeding (see section 4.6 Pregnancy and lactation)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients must be assessed prior to administration of ZOLENAT to ensure that they are adequately hydrated.</p><p>&nbsp;</p><p>Overhydration should be avoided in patients at risk of cardiac failure.</p><p>&nbsp;</p><p>Standard hypercalcemia-related metabolic parameters, such as corrected serum levels of calcium according to serum albumin, serum levels of phosphate and magnesium, should be carefully monitored after initiating ZOLENAT therapy. If hypocalcemia, hypophosphatemia, or hypomagnesaemia occurs, short-term supplemental therapy may be necessary. Untreated hypercalcemia patients generally have some degree of renal impairment, therefore careful renal function monitoring should be considered.</p><p>&nbsp;</p><p>Patients being treated with ZOLENAT should not be treated with other bisphosphonates or other drugs that contain zoledronic acid concomitantly, since the combined effects of these agents are unknown.</p><p>While not observed in clinical trials with ZOLENAT, there have been reports of bronchoconstriction in acetylsalicylic acid sensitive asthmatic patients receiving bisphosphonates.</p><p>&nbsp;</p><p><strong>Renal insufficiency:</strong></p><p>Patients with hypercalcemia of malignancy<strong> </strong>and evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of treatment with ZOLENAT outweighs the possible risk.</p><p>&nbsp;</p><p>The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2-3 months.</p><p><em>&nbsp;</em></p><p>Bisphosphonates has been associated with reports of renal dysfunction. Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of ZOLENAT and other bisphosphonates as well as use of other nephrotoxic medicinal products. While the risk is reduced with a dose of 4 mg ZOLENAT administered over 15 minutes, deterioration in renal function may still occur. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of zoledronic acid. Increases in serum creatinine also occur in some patients with chronic administration of ZOLENAT at recommended doses or prevention of skeletal related events, although less frequently.</p><p>&nbsp;</p><p>Patients should have their serum creatinine levels assessed prior to each dose of ZOLENAT. Upon initiation of treatment in patients with bone metastases with mild to moderate renal impairment, lower doses of ZOLENAT are recommended. In patients who show evidence of renal deterioration during treatment, ZOLENAT should only be resumed when serum creatinine levels return to within 10% of baseline (see section4.2 Posology and method of administration).</p><p>&nbsp;</p><p>The use of ZOLENAT is not recommended in patients with severe renal impairment because there are limited clinical safety and pharmacokinetic data in this population, and there is a risk of renal function deterioration in patients treated with bisphosphonates, including ZOLENAT.</p><p>&nbsp;</p><p>In clinical trials, patients with severe renal impairment were defined as those with baseline serum creatinine &ge;400 &micro;mol/l or &ge;4.5 mg/dl for cases of hypercalcemia of malignancy; &ge;265 &micro;mol/l or &ge;3.0 mg/dl for patients with cancer and bone metastases. In pharmacokinetic studies, patients with severe renal impairment were defined as those with baseline creatinine clearance &lt; 30 ml/min.</p><p>&nbsp;</p><p><strong>Hepatic insufficiency:</strong></p><p>As only limited clinical data are available in patients with severe hepatic insufficiency, no specific recommendations can be given for this patient population.</p><p>&nbsp;</p><p><strong>Osteonecrosis of the jaw (ONJ):</strong></p><p>Osteonecrosis of the jaw (ONJ) has been reported predominantly in patients treated with bisphosphonates, including zoledronic acid. Many of these patients were also receiving chemotherapy and corticosteroids. Many had signs of local infection including osteomyelitis.</p><p>&nbsp;</p><p>Post-marketing experience and the literature suggest a greater frequency of reports of osteonecrosis of the jaw based on tumor type (advanced breast cancer, multiple myeloma), and dental status (dental extraction, periodontal disease, local trauma including poorly fitting dentures).</p><p>&nbsp;</p><p>Cancer patients should maintain good oral hygiene and should have a dental examination with preventive dentistry prior to treatment with bisphosphonates.</p><p>&nbsp;</p><p>While on treatment, these patients should avoid invasive dental procedures if possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.</p><p>&nbsp;</p><p><strong>Atypical fractures of the femur:</strong></p><p>Atypical femoral fractures have been reported in patients receiving bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. These transverse or short oblique fractures can occur anywhere along the femur from just below the lesser trochanter to just above the supracondylar flare. These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with radiological imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. Fractures are often bilateral; therefore the contralateral femur should be examined in ZOLENAT-treated patients, who have experienced a femoral fracture. Poor healing of these fractures has also been reported. Discontinuation of ZOLENAT therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment. Reports of atypical femoral fracture have been received in patients treated with zoledronic acid; however causality with zoledronic acid therapy has not been established.</p><p>&nbsp;</p><p>During ZOLENAT treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.</p><p>&nbsp;</p><p><strong>Musculoskeletal pain:</strong></p><p>In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain have been reported in patients taking bisphosphonate including zoledronic acid (see section 4.8 Undesirable effects). The time to onset of symptoms varied from one day to several months after starting treatment. Most patients had relief of symptoms after stopping treatment. A subset had recurrence of symptoms when re-challenged with same medicine or another bisphosphonate.</p><p>&nbsp;</p><p><strong>Hypocalcemia:</strong></p><p>Cases of hypocalcaemia requiring hospitalization have been reported in patients treated with zoledronic acid. Cardiac arrhythmias and neurologic adverse events (including seizures, numbness and tetany) have been reported secondary to cases of severe hypocalcaemia. In some instances, the hypocalcaemia may be life threatening.</p><p>&nbsp;</p><p><strong>Sodium content:</strong></p><p>This medicinal product contains less than 1 mmol (23 mg) of sodium per 5 ml; no effect is expected due to sodium at this dose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Anticipated interactions to be considered:</strong></p><p>Caution is advised when bisphosphonates like ZOLENAT are administered with aminoglycosides or calcitonin or and loop diuretics, since these agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required.</p><p>&nbsp;</p><p>Caution is indicated when used in combination with other potentially nephrotoxic drugs.</p><p>&nbsp;</p><p>Caution is advised when bisphosphonates are administered with aminoglycosides, since both agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required.</p><p>&nbsp;</p><p>Caution is advised when zoledronic acid is administered with anti-angiogenic medicinal products as an increase in the incidence of osteonecrosis of the jaw has been observed in patients treated concomitantly with these medicinal products.</p><p>&nbsp;</p><p><strong>Absence of interactions:</strong></p><p>In clinical studies, zoledronic acid has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics and analgesics without clinically apparent interactions occurring.</p><p>&nbsp;</p><p>In multiple myeloma patients, the risk of renal dysfunction may be increased when intravenous bisphosphonates are used in combination with thalidomide.</p><p><strong>&nbsp;</strong></p><p><strong>Additional information regarding special populations:</strong></p><p>No clinical interaction studies conducted in special populations.</p><p>&nbsp;</p><p><strong>Pediatric population:</strong> No clinical interaction studies conducted regarding special pediatric population.</p><p><strong>&nbsp;</strong></p><p><strong>Renal insufficiency:</strong> No clinical interaction studies conducted in patients with renal insufficiency.</p><p>&nbsp;</p><p><strong>Hepatic insufficiency:</strong> No clinical interaction studies conducted in<strong> </strong>patients with hepatic insufficiency.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>General advice: </em></strong>Pregnancy category is D.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Women of childbearing potential / Birth control (Contraception)</strong></p><p>Women of childbearing potential should use an effective birth control during ZOLENAT treatment. ZOLENAT should not be used during pregnancy.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>Zoledronic acid causes<strong> </strong>harmful pharmacological effects during pregnancy and/or on the fetus/newborn child.</p><p>&nbsp;</p><p>ZOLENAT should not be used during pregnancy unless it is necessary.</p><p>&nbsp;</p><p><strong>Lactation</strong></p><p>There is insufficient/limited information on the excretion of zoledronic acid in human or animal milk. Due to available physicochemical and pharmacodynamic/toxicological data regarding excretion of zoledronic acid in milk the risk cannot be excluded to the breast fed child. ZOLENAT should not be used in lactation.</p><p>&nbsp;</p><p><strong>Reproduction ability /Fertility</strong></p><p>Zoledronic acid was evaluated in rats for potential adverse effects on fertility of the parental and F1 generation. This resulted in exaggerated pharmacological effects considered to be related to the compound&#39;s inhibition of skeletal calcium metabolization, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study. Thus these results are insufficient for determining a definitive effect of zoledronic</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of ZOLENAT along with driving and operating of machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a. Summary of the safety profile:</strong></p><p>Within three days after zoledronic acid administration, an acute phase reaction has commonly been reported, with symptoms including bone pain, fever, fatigue, arthralgia, myalgia and rigors; these symptoms usually resolve within a few days (see description of selected adverse reactions).</p><p>&nbsp;</p><p><u>The following are the important identified risks with ZOLENAT in the approved indications:</u></p><p>Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, ocular adverse events, atrial fibrillation and anaphylactic reaction. The frequencies for each of these identified adverse reactions are shown in below.</p><p>&nbsp;</p><p><strong>b. Tabulated summary of adverse reactions</strong></p><p>Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention. Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.</p><p>&nbsp;</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Common:</p></td><td><p>Anemia</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon:</p></td><td><p>Thrombocytopenia, leukopenia</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Rare:</p></td><td><p>Pancytopenia</p></td></tr><tr><td colspan="3"><p><strong>Immune system disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon:</p></td><td><p>Hypersensitivity reaction</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Rare:</p></td><td><p>Angioneurotic edema</p></td></tr><tr><td colspan="3"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon:</p></td><td><p>Anxiety, sleep disturbance</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Rare:</p></td><td><p>Confusion</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Common:</p></td><td><p>Headache</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon:</p></td><td><p>Dizziness, paresthesia, taste disturbance, hypoesthesia, hyperesthesia, tremor, somnolence</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Very rare</p></td><td><p>Seizures, numbness and tetany (secondary to hypocalcaemia)</p></td></tr><tr><td colspan="3"><p><strong>Eye disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Common:</p></td><td><p>Conjunctivitis</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon:</p></td><td><p>Blurred vision, scleritis and orbital inflammation</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Very rare:</p></td><td><p>Uveitis, episcleritis</p></td></tr><tr><td colspan="3"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon:</p></td><td><p>Hypertension, hypotension, atrial fibrillation, hypotension leading to syncope or circulatory collapse</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Rare:</p></td><td><p>Bradycardia</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Very rare:</p></td><td><p>Cardiac arrhythmia (secondary to hypocalcaemia)</p></td></tr><tr><td colspan="3"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon:</p></td><td><p>Dyspnea, cough, bronchoconstriction</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Rare:</p></td><td><p>Interstitial lung disease</p></td></tr><tr><td colspan="3"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Common:</p></td><td><p>Nausea, vomiting, anorexia</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon:</p></td><td><p>Diarrhea, constipation, abdominal pain, dyspepsia, stomatitis, dry mouth</p></td></tr><tr><td colspan="3"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon:</p></td><td><p>Pruritus, rash (including erythematous and macular rash), increased sweating</p></td></tr><tr><td colspan="3"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Common:</p></td><td><p>Bone pain, myalgia, arthralgia, generalized pain</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon:</p></td><td><p>Muscle cramps, osteonecrosis of the jaw</p></td></tr><tr><td colspan="3"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Common:</p></td><td><p>Renal impairment</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon:</p></td><td><p>Acute renal failure, hematuria, proteinuria</p></td></tr><tr><td colspan="3"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Common:</p></td><td><p>Fever, flu-like syndrome (including fatigue, rigors, malaise and flushing)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon:</p></td><td><p>Asthenia, peripheral edema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, anaphylactic reaction/shock, urticaria</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Rare:</p></td><td><p>Arthritis and joint swelling as a symptom of acute phase reaction</p></td></tr><tr><td colspan="3"><p><strong>Laboratory findings</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Very common:</p></td><td><p>Hypophosphatemia</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Common:</p></td><td><p>Blood creatinine and blood urea increased, hypocalcaemia</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon:</p></td><td><p>Hypomagnesaemia, hypokalemia</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Rare:</p></td><td><p>Hyperkalemia, hypernatremia</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>c. Description of selected adverse reactions:</strong></p><p>&nbsp;</p><p><strong>Renal function impairment:</strong></p><p>Zoledronic acid has been associated with reports of renal dysfunction. In a pooled analysis of safety data from zoledronic acid registration trials for the prevention of skeletal-related events in patients with advanced malignancies involving bone, the frequency of renal impairment adverse events suspected to be related to zoledronic acid (adverse reactions) was as follows: Multiple myeloma (3.2%), prostate cancer (3.1%), breast cancer (4.3%), lung and other solid tumors (3.2%). Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of ZOLENAT or other bisphosphonates, as well as concomitant use of nephrotoxic medicinal products or using a shorter infusion time than currently recommended. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of zoledronic acid (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p><strong>Osteonecrosis of the iaw:</strong></p><p>Cases of osteonecrosis (primarily of the jaws) have been reported, predominantly in cancer patients treated with bisphosphonates including zoledronic acid. Many of these patients had signs of local infection including osteomyelitis, and the majority of the reports refer to cancer patients following tooth extractions or other dental surgeries. Osteonecrosis of the jaws has multiple documented risk factors including a diagnosis of cancer, concomitant therapies (e.g. chemotherapy, radiotherapy, corticosteroids) and co-morbid conditions (e.g. anemia, coagulopathies, infection, pre-existing oral disease). Although causality has not been determined, it is recommended to avoid dental surgery as recovery may be prolonged (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p><strong>Atrial fibrillation:</strong></p><p>In one 3-year, randomized, double-blind controlled trial that evaluated the efficacy and safety of zoledronic acid 5 mg once yearly vs. placebo in the treatment of postmenopausal osteoporosis (PMO), the overall incidence of atrial fibrillation was 2.5% (96 out of 3862) and 1.9% (75 out of 3852) in patients receiving zoledronic acid 5 mg and placebo, respectively. The rate of atrial fibrillation serious adverse events was 1.3% (51 out of 3862) and 0.6% (22 out of 3852) in patients receiving zoledronic acid 5 mg and placebo, respectively. The imbalance observed in this trial has not been observed in other trials with zoledronic acid, including those with zoledronic acid 4 mg every 3-4 weeks in oncology patients. The mechanism behind the increased incidence of atrial fibrillation in this single clinical trial is unknown.</p><p>&nbsp;</p><p><strong>Acute phase reaction:</strong></p><p>This adverse drug reaction consists of a constellation of symptoms that includes fever, myalgia, headache, extremity pain, nausea, vomiting, diarrhea and joint pain. The onset time is &le; 3 days post zoledronic acid infusion, and the reaction is also referred to using the terms &quot;flu-like&quot; or &quot;post-dose&quot; symptoms.</p><p>&nbsp;</p><p><strong>Atvpical fractures of the femur:</strong></p><p>During post-marketing experience the following reactions have been reported (frequency rare): Atypical subtrochanteric and diaphyseal femoral fractures (bisphopsphonate class adverse reaction).</p><p>&nbsp;</p><p><strong>Hypocalcaemia-related adverse reactions:</strong></p><p>Hypocalcaemia is an important identified risk with ZOLENAT in the approved indications. Based on the review of both clinical trial and post-marketing cases, there is sufficient evidence to support an association between ZOLENAT therapy, the reported event of hypocalcaemia, and the secondary development of cardiac arrhythmia. Furthermore, there is evidence of an association between hypocalcaemia and secondary neurological events reported in these cases including: seizures, numbness and tetany (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical experience with acute overdose of zoledronic acid is limited. The administration of doses up to 48 mg of zoledronic acid in error has been reported. Patients who have received doses higher than those recommended should be carefully monitored, since renal function impairment (including renal failure) and serum electrolyte (including calcium, phosphorus and magnesium) abnormalities have been observed (see section 4.2 Posology and method of administration). In the event of hypocalcaemia, calcium gluconate infusions should be administered as clinically indicated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Bisphosphonates</p><p>ATC code: M05BA08</p><p>&nbsp;</p><p>Zoledronic acid belongs to the class of bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclastic bone resorption.</p><p>&nbsp;</p><p>The selective action of bisphosphonates on bone is based on their high affinity for mineralized bone, but the precise molecular mechanism leading to the inhibition of osteoclastic activity is still unclear. In long-term animal studies, zoledronic acid inhibits bone resorption without adversely affecting the formation, mineralization or mechanical properties of bone.</p><p>&nbsp;</p><p>In addition to being a potent inhibitor of bone resorption, zoledronic acid also possesses several anti-tumor properties that could contribute to its overall efficacy in the treatment of metastatic bone disease. The following properties have been demonstrated in preclinical studies:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>In vivo: </em>Inhibition of osteoclastic bone resorption, which alters the bone marrow microenvironment, making it less conducive to tumor cell growth, anti-angiogenic activity and anti-pain activity.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>In vitro: </em>Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity on tumor cells, synergistic cytostatic effect with other anti-cancer drugs, anti-adhesion/invasion activity.</p><p>&nbsp;</p><p><strong>Clinical trial results in the prevention of skeletal related events in patients with advanced malignancies involving bone:</strong></p><p>Zoledronic acid was compared to placebo for the prevention of skeletal related events (SREs) in adult prostate cancer patients with 214 men receiving zoledronic acid 4 mg versus 208 receiving placebo. After the initial 15 months of treatment, 186 patients continued for up to an additional 9 months, giving a total duration of double-blind therapy up to 24 months. Zoledronic acid 4 mg demonstrated a significant advantage over placebo for the proportion of patients experiencing at least one skeletal related event (SRE) (38% for zoledronic acid 4 mg versus 49 % for placebo, p=0.028), delayed the median time to first SRE (488 days for zoledronic acid 4 mg versus 321 days for placebo, p=0.009), and reduced the annual incidence of event per patient &ndash; skeletal morbidity rate (0.77 for zoledronic acid 4 mg versus 1.47 for placebo, p=0.005). Multiple event analysis showed 36% risk reduction in developing skeletal related events in the zoledronic acid group compared with placebo (p=0.002). Pain was measured at baseline and periodically throughout the trial. Patients receiving zoledronic acid reported less increase in pain than those receiving placebo, and the differences reached significance at months 3, 9, 21 and 24. Fewer zoledronic acid patients suffered pathological fractures. The treatment effects were less pronounced in patients with blastic lesions.</p><p>&nbsp;</p><p>In a second study, zoledronic acid reduced the number of SREs and extended the median time to an SRE by over two months in the population of adult patients who had other solid tumors involving bone, which had a median survival of only six months (134 patients with non-small cell lung cancer [NSCLC], 123 with other solid tumors treated with zoledronic acid vs 130 patients with NSCLC, 120 with other solid tumors treated with placebo). After initial 9 months of treatment, 101 patients entered the 12 month extension study, and 26 completed the full 21 months. Zoledronic acid 4 mg reduced the proportion of patients with SREs (39% for zoledronic acid 4 mg versus 48% for placebo, p=0.039), delayed the median time to first SRE (236 days for zoledronic acid 4 mg versus 155 days for placebo, p=0.009), and reduced the annual incidence of events per patient - skeletal morbidity rate (1.74 for zoledronic acid 4 mg versus 2.71 for placebo, p=0.012). Multiple event analysis showed 30.7% risk reduction in developing skeletal related events in the zoledronic acid group compared with placebo (p=0.003). The treatment effect in non-small cell lung cancer patients appeared to be smaller than in patients with other solid tumors.</p><p>&nbsp;</p><p>In a third phase III randomized, double-blind trial comparing zoledronic acid 4 mg to pamidronate 90 mg, 1122 adult patients (564 zoledronic acid 4 mg, 558 pamidronate 90 mg) with multiple myeloma or breast cancer with at least one bone lesion were treated with 4 mg zoledronic acid or 90 mg pamidronate every 3 to 4 weeks.. 606 patients entered the 12-month, doubleblind extension phase. Total therapy lasted up to 24 months. The results demonstrated that zoledronic acid 4 mg showed comparable efficacy to 90 mg pamidronate in the prevention of skeletal related events. The multiple event analyses revealed a significant risk reduction of 16 % (p=0.030) in patients treated with zoledronic acid 4 mg.</p><p>&nbsp;</p><p>In clinical trials performed in adult patients with bone metastases or osteolytic lesions, the overall safety profile amongst all treatment groups (zoledronic acid 4 mg, and pamidronate 90 mg and placebo) was similar in types and severity.</p><p>&nbsp;</p><p>Zoledronic acid was also studied in a double-blind, randomized, placebo-controlled trial in 228 adult patients with documented bone metastases from breast cancer to evaluate the effect of zoledronic acid on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcemia and adjusted for prior fracture), divided by the total risk period. Patients received either 4 mg zoledronic acid or placebo every four weeks for one year. Patients were evenly distributed between zoledronic acid -treated and placebo groups. The SRE rate ratio at one year was 0.61, indicating that treatment with zoledronic acid reduced the rate of occurrence of SREs by 39% compared with placebo (p=0.027). The proportion of patients with at least one SRE (excluding hypercalcemia) was 29.8% in the zoledronic acid &ndash;treated group versus 49.6% in the placebo group (p=0.003). Median time to onset of the first SRE was not reached in the zoledronic acid -treated arm at the end of the study and was significantly prolonged compared to placebo (p=0.007). Zoledronic acid reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.</p><p>&nbsp;</p><p>In the zoledronic acid -treated group, decreases in pain scores from baseline (using the Brief Pain Inventory, BPI) occurred from 4 weeks onwards and at every subsequent time point during the study, while the pain score in the placebo group remained unchanged or increased from baseline. Zoledronic acid inhibited the worsening of the analgesic score more than placebo. In addition, 71.8% of zoledronic acid -treated patients versus 63.1% of placebo patients showed improvement or no change in the ECOG performance score at the final observation.</p><p><strong>&nbsp;</strong></p><p><strong>Clinical trial results in the treatment of hypercalcemia of malignancy:</strong></p><p>Clinical studies in hypercalcemia of malignancy demonstrated that the effect of zoledronic acid is characterized by decreases in serum calcium and urinary calcium excretion.</p><p>&nbsp;</p><p>To assess the effects of zoledronic acid versus pamidronate 90 mg, the results of two pivotal multicenter studies in adult patients with TIH were combined in a pre-planned analysis. The results showed that zoledronic acid 4 mg and 8 mg were statistically superior to pamidronate 90 mg for the proportion of complete responders at day 7 and day 10. There was faster normalization of corrected serum calcium at day 4 for zoledronic acid 8 mg and at day 7 for zoledronic acid 4 mg and 8 mg. Median time to normocalcemia was 4 days. By day 10 the response rate was 87 to 88% for the zoledronic acid treatment groups versus 70% for pamidronate 90 mg. Median time to relapse (re-increase of albumin-corrected serum calcium &ge;2.9 mmol/L) was 30 to 40 days for patients treated with zoledronic acid versus 17 days for those treated with pamidronate 90 mg. The results showed that both zoledronic acid doses were statistically superior to pamidronate 90 mg for time to relapse. There were no statistically significant differences between the two zoledronic acid doses.</p><p>&nbsp;</p><p>In clinical trials performed in adult patients with tumor-induced hypercalcemia (TIH), the overall safety profile amongst all three treatment groups (zoledronic acid 4 and 8 mg and pamidronate 90 mg) was similar in types and severity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>General properties</strong></p><p>Zoledronic acid monohydrate is a white, crystal, odorless powder. Soluble in 0.1 M sodium hydroxide; sparingly soluble in water and 0.1 M hydrochloric acid; insoluble in ethanol and methanol.</p><p>&nbsp;</p><p><u>Absorption:</u></p><p>Single and multiple 5- and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64&nbsp;&nbsp; patients with bone metastases yielded the following pharmacokinetic data, which were found to be dose independent.</p><p>After initiating the infusion of zoledronic acid, the plasma concentrations of drug rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to &lt;10% of peak after 4 hours and &lt;1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of drug on day 28.</p><p>&nbsp;</p><p><u>Distribution:</u></p><p>Zoledronic acid shows no affinity for the cellular components of blood and plasma protein binding is low (approximately 56%) and independent of the concentration of zoledronic acid.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Biotransformation:</u></p><p>Zoledronic acid is not metabolized and is excreted unchanged via the kidney. Over the first 24 hours, 39 &plusmn; 16% of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue. From the bone tissue it is released very slowly back into the systemic circulation and eliminated via the kidney. The total body clearance is 5.04 &plusmn; 2.5 L/h, independent of dose, and unaffected by gender, age, race, and body weight. Zoledronic acid does not inhibit human P450 enzymes <em>in vitro</em>.</p><p>&nbsp;</p><p><u>Elimination: </u></p><p>Intravenously administered zoledronic acid is eliminated via a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t&frac12;alpha 0.24 and t&frac12;beta 1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t&frac12;gamma 146 hours. There was no accumulation of drug in plasma after multiple doses of the drug given every 28 days.</p><p>&nbsp;</p><p><u>Linearity/non-linearity:</u></p><p>Pharmacokinetics of zoledronic acid is determined as dose dependent. Increasing the infusion time from 5 to 15 minutes caused a 30% decrease in zoledronic acid concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve.</p><p>&nbsp;</p><p><strong>Characteristics in patients</strong></p><p><strong><em>&nbsp;</em></strong></p><p><u>Renal insufficiency:</u></p><p>The renal clearance of zoledronic acid was significantly positively correlated with creatinine clearance, renal clearance representing 75%&plusmn;33% of the creatinine clearance, which showed a mean of 84&plusmn;29 ml/min (range 22 to 143 ml/min) in the 64 cancer patients studied. Population analysis showed that for a patient with creatinine clearance of 20 ml/min (severe renal impairment), or 50 ml/min (moderate impairment), the corresponding predicted clearance of zoledronic acid would be 72%, of that of a patient showing creatinine clearance of 84 ml/min. Only limited pharmacokinetic data are available in patients with severe renal insufficiency (creatinine clearance &lt;30 ml/min). The use of ZOLENAT is not recommended in patients with severe renal impairment.</p><p>&nbsp;</p><p><u>Hypercalcemia or Hepatic insufficiency:</u></p><p>No pharmacokinetic data for zoledronic acid are available in patients with hypercalcemia or in patients with hepatic insufficiency. Zoledronic acid does not inhibit human P450 enzymes <em>in vitro</em>, shows no biotransformation and in animal studies &lt;3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.</p><p>&nbsp;</p><p><u>Effect of gender, age and race:</u></p><p>The three pharmacokinetic studies conducted in cancer patients with bones metastases reveal no effect by gender, race, age (range 38 to 84 years), and body weight on zoledronic acid total clearance.</p><p>&nbsp;</p><p><u>Pediatric patients: </u></p><p>Limited pharmacokinetic data in pediatric populations are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Acute toxicity</strong></p><p>The highest non-lethal single intravenous dose was 10 mg/kg bodyweight in mice and 0.6 mg/kg in rats.</p><p><strong>Sub-chronic and chronic toxicity</strong></p><p>Zoledronic acid was well tolerated when administered subcutaneously to rats and intravenously to dogs at doses up to 0.02 mg/kg daily for 4 weeks. Administration of 0.001 mg/kg/day subcutaneously in rats and 0.005 mg/kg intravenously once every 2-3 days in dogs for up to 52 weeks was also well tolerated.</p><p>&nbsp;</p><p><strong>Reproduction toxicity</strong></p><p>Zoledronic acid was teratogenic in the rat at subcutaneous doses &ge;0.2 mg/kg. Although no teratogenicity or foetotoxicity was observed in the rabbit, maternal toxicity was found.</p><p>&nbsp;</p><p><strong>Mutagenicity and carcinogenic potential</strong></p><p>Zoledronic acid was not mutagenic in the mutagenicity tests performed and carcinogenicity testing did not provide any evidence of carcinogenic potential.</p><p>&nbsp;</p><p><strong>Local tolerance</strong></p><p>Local tolerance testing in rabbits showed that intravenous administration was well tolerated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Sodium citrate</p><p>Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Studies with infusion bags pre-filled with 0.9% sodium chloride solution or 5% dextrose solution showed no incompatibility with ZOLENAT.</p><p>&nbsp;</p><p>To avoid potential incompatibilities, ZOLENAT concentrate is to be diluted with 0.9% sodium chloride solution or 5% dextrose solution.</p><p>&nbsp;</p><p>ZOLENAT concentrate must not be mixed or come into contact with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer&rsquo;s solution, and should be administered as a single intravenous solution in a line separate from all other drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store the vial at room temperature below 30&deg;C.</p><p>&nbsp;</p><p>ZOLENAT 4 mg/5ml Concentrate for Solution for IV Infusion is for intravenous use only.</p><p>Before administration the 5.0 ml within the vial or the needed volume concentrated solution should be diluted with calcium-free infusion solution (0.9% sodium chloride solution or 5% dextrose solution). ZOLENAT solution is stable for 24 hours at 2 to 8&deg;C following dilution with 0.9% sodium chloride solution or 5% dextrose solution. After aseptic dilution, it is preferable to use the diluted product immediately. If not used immediately, the duration and conditions of storage prior to use are under the healthcare provider&rsquo;s responsibility. The refrigerated solution should then be equilibrated to room temperature prior to administration. The total time between dilution, storage in a refrigerator at 2 to 8&deg;C and end of administration must not exceed 24 hours. (See section 4.2 Posology and method of administration)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ZOLENAT 4 mg/5 ml Concentrate for solution for IV infusion is presented in Type I glass vials.</p><p>&nbsp;</p><p>Each carton contains 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local disposal regulations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MN Pharmaceuticals 
İş Kuleleri, Levent Mah., Meltem Sok. 
No: 10 Kule: 2 Kat: 24 
4. Levent, Beşiktaş, İstanbul/TURKEY 
Tel: +90.212 337 38 00 
Fax: +90.212.337 38 01 
e-mail: info@mn.com.tr

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>